Skip to main content
BioNxt Solutions Inc. logo

BioNxt Solutions Inc. — Investor Relations & Filings

Ticker · BNXT ISIN · CA0909741062 LEI · 254900VZ478Z39V2NM18 CSE Manufacturing
Open in API
Filings indexed 244 across all filing types
Latest filing 2025-06-26 Audit Report / Informat…
Country CA Canada
Listing CSE BNXT

About BioNxt Solutions Inc.

https://bionxt.com/

BioNxt Solutions Inc. is a clinical-stage bioscience company focused on developing next-generation drug formulations and advanced delivery systems. The company specializes in high-performance solutions, including sublingual thin films and transdermal patches, designed to enhance bioavailability and patient compliance across critical therapeutic areas. BioNxt's R&D pipeline targets neurology, immunology, oncology, and mental health. Core platforms include advanced drug delivery systems for chronic diseases, a targeted chemotherapy platform designed to reduce systemic toxicity by delivering cytotoxic agents directly to tumors, and a proprietary library of engineered psychedelic compounds for neurological and psychiatric conditions. The company also develops diagnostic screening tests and active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document is titled “Consolidated Financial Statements” for the years ended December 31, 2024 and 2023 and begins with an Independent Auditor’s Report. It contains the auditor’s opinion, basis for opinion, key audit matters, and then detailed consolidated statements of financial position, loss and comprehensive loss, cash flows, and related notes. There is no narrative MD&A or broader corporate annual report cover letter, only the audited financial statements and audit report. This matches a standalone Audit Report / Information filing rather than a full Annual Report (10-K), making Code “AR” the appropriate classification. FY 2024
2025-06-26 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing a feasibility study for an oral thin film formulation of Semaglutide. It contains no financial results, no meeting materials, no management or board changes, no capital transaction, no voting or dividend details, and no specific regulatory form. It is a general company announcement about R&D progress, which does not match any specific category except the fallback ‘Regulatory Filings’ (RNS).
2025-06-25 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing the European Patent Office’s intention to grant BioNxt Solutions a core patent. It is not a financial report, management change, share transaction, dividend notice, or any other specified category. This type of announcement does not fit any of the highly specific categories, so it falls under the general regulatory/press release catch-all. Therefore, it should be classified as a Regulatory Filing (RNS).
2025-05-26 English
News release - English.pdf
Report Publication Announcement Classification · 1% confidence The document is a corporate news release announcing a delay in filing the company’s Annual Financial Statements and providing revised expected filing dates. It does not contain the actual financial statements, MD&A or certifications, but rather informs investors of a timing change. It is therefore not the annual report itself (10-K/AR) but a notice regarding the timing/publication of that report. This fits the “Report Publication Announcement” category (RPA).
2025-05-02 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing BioNxt’s operational update—preparation for a human bioequivalence study—rather than a regulatory form (e.g., a financial report, dividend notice, or proxy statement). It does not fit any specific category like earnings release, capital raising, management change, or ESG report. As a generic company announcement filed with regulators, it defaults to the fallback “Regulatory Filings” category (RNS).
2025-04-23 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a news release announcing the closing of the final tranche of a non‐brokered private placement of convertible debentures, detailing the amounts raised, securities issued, warrants, use of proceeds, and fees paid. This is clearly an update on the company’s fundraising and financing activities, fitting the definition of a Capital/Financing Update (CAP).
2025-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.